Explore By Subject Area   
Return Home
Register Here Menu

Immuno-Oncology 360°

Date: Mar 24, 2025 - Mar 26, 2025

Location: Boston, MA

Day Two: Tuesday, March 25, 2025
Showing Events in 1 Track from 07:45am to 08:20am
Morning Remarks
7:45AM - 8:10AM
Registration & 1:1 Partnering Meetings
8:10AM - 8:20AM
Day Two Welcome
Co-Chair:
Daniel S Chen, MD, PhD, Founder, Engenuity Life Sciences
Showing Events in 1 Track from 08:20am to 09:25am
State of the IO Market, Investments and Deals Plenary
8:20AM - 8:45AM
Keynote: Pushing the Boundaries of Investments and Adapting to the IO Market Dynamics
Keynote Speaker:
Arie Belldegrun, MD, Executive Chairman & Co-founder, Allogene
8:45AM - 9:05AM
Fireside Chat with Pfizer's Chief Innovation & Strategy Officer, Dr Andrew Baum
Fireside Guest:
Andrew Baum, MD, Chief Strategy and Innovation Officer, Pfizer
Moderator:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
9:05AM - 9:25AM
Biotech Markets & IO Outlook
Showing Events in 1 Track from 09:25am to 09:45am
IO Clinical Trial Impact: A Patient Perspective
9:25AM - 9:45AM
Fireside Chat: The Personal Impact of an Immunotherapy Trial
Showing Events in 1 Track from 09:45am to 10:25am
Morning IO360° Breakfast, Networking, Exhibits & 1:1 Partnering Meetings
9:45AM - 10:25AM
Morning IO360° Breakfast, Networking, Exhibits & 1:1 Partnering Meetings
Showing Events in 1 Track from 10:25am to 11:05am
IO360º Biotech Showcase
10:25AM - 11:00AM
IO360° Biotech Showcase
11:00AM - 11:05AM
5 Minute Health Break
Showing Events in 1 Track from 11:05am to 12:25pm
State of the IO Market, Investments and Deals Plenary (continued)
11:05AM - 11:45AM
Business Development Strategies in IO: M&A, Partnerships, and Biotech Investments
Moderator:
Andrew Baum, MD, Chief Strategy and Innovation Officer, Pfizer
Panelists:
Rick Aldridge, MBChB, Managing Director, Healthcare, Lazard
Rakhshita Dhar, Senior Director, Venture Investments, Health, Leaps by Bayer
Emmett Schmidt, MD, PhD, VP, Clinical Oncology and Lead, External Collaborations, Merck
Gayatri Varma, PhD, Executive Director and Head of Transactions, Oncology R&D, AstraZeneca
11:45AM - 12:25PM
Navigating Immuno-Oncology Investments in 2025: Fundraising in Capital Markets
Moderator:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
Panelists:
Kalli Dircks, Managing Director, Global Capital Markets, Morgan Stanley
Carl Gordon, PhD, CFA, Managing Partner, OrbiMed Advisors LLC
Rajiv Kaul, Portfolio Manager, Equity Division, Fidelity Investments
Showing Events in 1 Track from 12:25pm to 01:30pm
Lunch
12:25PM - 1:30PM
Lunch & 1:1 Partnering Meetings
Showing Events in 2 Tracks from 01:30pm to 03:05pm
Track 1: Breakthroughs in Translational Science, Imaging and Biomarkers (Pt 2)
1:30PM - 1:50PM
Advancing CAR T Therapies: A New BCMA/CD19 Approach for Treating Multiple Myeloma
Speaker:
Nina Shah, MD, Global Head of Multiple Myeloma Clinical Development and Strategy, Hematology R&D, AstraZeneca
1:50PM - 2:10PM
IO Combo with PD1, TGIT and Other Members of the CD226 Axis
2:25PM - 3:05PM
Panel: AI's Role in Advancing Immuno-Oncology R&D Strategies
Panelists:
Sharon Benzeno, PhD, MBA, Chief Commercial Officer, Immune Medicine, Adaptive Biotechnologies
S. Chakra Chennubhotla, PhD, Chief of AI & CO, PredXBio
Track 2: IO Cell Therapy
1:30PM - 1:50PM
Evolution and Future Directions in Cell Therapy: Overcoming Challenges and Pioneering Innovations
1:50PM - 2:10PM
Innovations in Manufacturing and Potency Enhancement for Enhanced Accessibility and Affordability
Speaker:
Greg Sawyer, PhD, Chief BioEngineering Officer, Chair, Department of BioEngineering, Moffitt Cancer Center
2:25PM - 3:05PM
Panel: Addressing the Realities of Scalability in T-Cell Therapies - Achieving Accessible and Affordable Treatment for All
Panelists:
Mark Cobbold, PhD, Head of Immuno-Oncology, Discovery and the Oncology Cell Therapy Unit, AstraZeneca
Arvind Natarajan, PhD, MBA, SVP, Process and Analytical Development, Iovance Biotherapeutics Inc
Showing Events in 1 Track from 03:20pm to 04:00pm
Afternoon Break
3:20PM - 4:00PM
Afternoon Networking Break & 1:1 Partnering Meetings
Showing Events in 4 Tracks from 04:00pm to 05:25pm
Track 1: Breakthroughs in Translational Science, Imaging and Biomarkers 1
4:00PM - 4:20PM
Next Generation CAR-T Therapy for Cancer and Autoimmune Disease
Speaker:
Naiyer Rizvi, MD, CMO, Synthekine
4:35PM - 4:55PM
Advancements in Tumor Targeting: Clinical and Preclinical Insights from DK210 (EGFR)
Speaker:
John Mumm, PhD, President & CEO, DEKA Biosciences
5:10PM - 5:25PM
Innovative Non-Cell CAR-T Strategies: Harnessing Bispecifics and Co-Stimulators for Enhanced Immunotherapy
Speakers:
Johanna Bendell, MD, Global Head Oncology, Pharma Research and Early Development, Roche
Ashley Lakner, Head, Oncology Discovery - pRED Oncology, Roche
Track 2: Breakthroughs in Translational Science, Imaging and Biomarkers 2
4:00PM - 4:20PM
Active Immunotherapy to Achieve Durable Remissions in MRD + AML
Speaker:
Erik Manting, PhD, CEO, Mendus
4:35PM - 4:55PM
Designing Next-Generation T-Cell Engagers for High Potency and Minimal Cytokine Release
Speaker:
Raffi Tonikian, PhD, Director, Translational Biomarkers, AbCellera
5:10PM - 5:25PM
Targeting Metastatic Cancer and Immune Resistance Using Nucleic Acid Therapies
Speaker:
Zdravka Medarova, PhD, CSO & Co-founder, TransCode Therapeutics
Track 3: Cell Therapy - Innovations in Process to Generate Cell Therapies
4:00PM - 4:15PM
Accelerating Cell Therapy: Innovations in Streamlining the Cell Manufacturing Process
Speaker:
Saba Ghassemi, PhD, Research Assistant; Professor of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
4:15PM - 4:30PM
Innovations in Point of Care and Extracorporeal Cell Delivery Technologies
Speaker:
Maurits Geerlings, MD, MBA, President & CEO, NanoCell Therapeutics, Inc
4:30PM - 4:45PM
In Vivo CD19 and CD22 CAR-T Cell Therapeutics for B Cell Malignancies
Speaker:
Andrew Scharenberg, MD, Co-Founder & CEO, Umoja Biopharma
4:45PM - 5:00PM
Implantable Biofactories for Bedside CAR T Cell Therapy
Speaker:
Yevgeny Brudno, PhD, Associate Professor, University of North Carolina at Chapel Hill and North Carolina State University
5:00PM - 5:15PM
Multiplexed CRISPR Cas9 Editing to Generate Next-Generation Allogeneic CAR-T Cells
Speaker:
Birgit Schultes, PhD, SVP, Head of Cell Therapies, Intellia Therapeutics
Track 4: Cell Therapy - Innovations in Cell Types Employed in Cell Therapies
4:00PM - 4:15PM
Advancing Cell Therapy Efficacy with Non-Viral Engineering Technologies
Speaker:
Loïc Vincent, PhD, CSO, Affini-T
4:15PM - 4:30PM
Peripheral Tumor Reactive Cells
Speaker:
Ruben Rodriguez, PhD, Head of Research, cTRL Therapeutics
4:30PM - 4:45PM
Engineered B Cells
Speaker:
Joanne Smith-Farrell, PhD, CEO & Director, Be Bio
4:45PM - 5:00PM
Clinical Biomarkers and Progress for Advancing Gamma-Delta CAR T Cells in Multiple Disease Settings
Speaker:
Blake Aftab, PhD, CSO, Adicet Bio
5:00PM - 5:15PM
Alternative Delivery Systems Spotlight Talks
Showing Events in 1 Track from 05:30pm to 06:30pm
IO360º Cancer Immunotherapy Debate
5:30PM - 6:30PM
IO360º Annual Debate: Monotherapy vs Combination Therapies in IO
Participants:
Alexander Eggermont, MD, PhD, CSO / Professor, Clinical & Translational Immunotherapy, Princess Máxima Center for Pediatric Oncology / UMC Utrecht, Utrecht University
Naiyer Rizvi, MD, CMO, Synthekine
Led by:
Daniel S Chen, MD, PhD, Founder, Engenuity Life Sciences
Showing Events in 1 Track from 07:45am to 08:20am
Morning Remarks
7:45AM - 8:10AM
Registration & 1:1 Partnering Meetings
8:10AM - 8:20AM
Day Two Welcome
Co-Chair:
Daniel S Chen, MD, PhD, Founder, Engenuity Life Sciences
Showing Events in 1 Track from 08:20am to 09:25am
State of the IO Market, Investments and Deals Plenary
8:20AM - 8:45AM
Keynote: Pushing the Boundaries of Investments and Adapting to the IO Market Dynamics
Keynote Speaker:
Arie Belldegrun, MD, Executive Chairman & Co-founder, Allogene
8:45AM - 9:05AM
Fireside Chat with Pfizer's Chief Innovation & Strategy Officer, Dr Andrew Baum
Fireside Guest:
Andrew Baum, MD, Chief Strategy and Innovation Officer, Pfizer
Moderator:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
9:05AM - 9:25AM
Biotech Markets & IO Outlook
Showing Events in 1 Track from 09:25am to 09:45am
IO Clinical Trial Impact: A Patient Perspective
9:25AM - 9:45AM
Fireside Chat: The Personal Impact of an Immunotherapy Trial
Showing Events in 1 Track from 09:45am to 10:25am
Morning IO360° Breakfast, Networking, Exhibits & 1:1 Partnering Meetings
9:45AM - 10:25AM
Morning IO360° Breakfast, Networking, Exhibits & 1:1 Partnering Meetings
Showing Events in 1 Track from 10:25am to 11:05am
IO360º Biotech Showcase
10:25AM - 11:00AM
IO360° Biotech Showcase
11:00AM - 11:05AM
5 Minute Health Break
Showing Events in 1 Track from 11:05am to 12:25pm
State of the IO Market, Investments and Deals Plenary (continued)
11:05AM - 11:45AM
Business Development Strategies in IO: M&A, Partnerships, and Biotech Investments
Moderator:
Andrew Baum, MD, Chief Strategy and Innovation Officer, Pfizer
Panelists:
Rick Aldridge, MBChB, Managing Director, Healthcare, Lazard
Rakhshita Dhar, Senior Director, Venture Investments, Health, Leaps by Bayer
Emmett Schmidt, MD, PhD, VP, Clinical Oncology and Lead, External Collaborations, Merck
Gayatri Varma, PhD, Executive Director and Head of Transactions, Oncology R&D, AstraZeneca
11:45AM - 12:25PM
Navigating Immuno-Oncology Investments in 2025: Fundraising in Capital Markets
Moderator:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
Panelists:
Kalli Dircks, Managing Director, Global Capital Markets, Morgan Stanley
Carl Gordon, PhD, CFA, Managing Partner, OrbiMed Advisors LLC
Rajiv Kaul, Portfolio Manager, Equity Division, Fidelity Investments
Showing Events in 1 Track from 12:25pm to 01:30pm
Lunch
12:25PM - 1:30PM
Lunch & 1:1 Partnering Meetings
Showing Events in 2 Tracks from 01:30pm to 03:05pm
Track 1: Breakthroughs in Translational Science, Imaging and Biomarkers (Pt 2)
1:30PM - 1:50PM
Advancing CAR T Therapies: A New BCMA/CD19 Approach for Treating Multiple Myeloma
Speaker:
Nina Shah, MD, Global Head of Multiple Myeloma Clinical Development and Strategy, Hematology R&D, AstraZeneca
1:50PM - 2:10PM
IO Combo with PD1, TGIT and Other Members of the CD226 Axis
2:25PM - 3:05PM
Panel: AI's Role in Advancing Immuno-Oncology R&D Strategies
Panelists:
Sharon Benzeno, PhD, MBA, Chief Commercial Officer, Immune Medicine, Adaptive Biotechnologies
S. Chakra Chennubhotla, PhD, Chief of AI & CO, PredXBio
Track 2: IO Cell Therapy
1:30PM - 1:50PM
Evolution and Future Directions in Cell Therapy: Overcoming Challenges and Pioneering Innovations
1:50PM - 2:10PM
Innovations in Manufacturing and Potency Enhancement for Enhanced Accessibility and Affordability
Speaker:
Greg Sawyer, PhD, Chief BioEngineering Officer, Chair, Department of BioEngineering, Moffitt Cancer Center
2:25PM - 3:05PM
Panel: Addressing the Realities of Scalability in T-Cell Therapies - Achieving Accessible and Affordable Treatment for All
Panelists:
Mark Cobbold, PhD, Head of Immuno-Oncology, Discovery and the Oncology Cell Therapy Unit, AstraZeneca
Arvind Natarajan, PhD, MBA, SVP, Process and Analytical Development, Iovance Biotherapeutics Inc
Showing Events in 1 Track from 03:20pm to 04:00pm
Afternoon Break
3:20PM - 4:00PM
Afternoon Networking Break & 1:1 Partnering Meetings
Showing Events in 4 Tracks from 04:00pm to 05:25pm
Track 1: Breakthroughs in Translational Science, Imaging and Biomarkers 1
4:00PM - 4:20PM
Next Generation CAR-T Therapy for Cancer and Autoimmune Disease
Speaker:
Naiyer Rizvi, MD, CMO, Synthekine
4:35PM - 4:55PM
Advancements in Tumor Targeting: Clinical and Preclinical Insights from DK210 (EGFR)
Speaker:
John Mumm, PhD, President & CEO, DEKA Biosciences
5:10PM - 5:25PM
Innovative Non-Cell CAR-T Strategies: Harnessing Bispecifics and Co-Stimulators for Enhanced Immunotherapy
Speakers:
Johanna Bendell, MD, Global Head Oncology, Pharma Research and Early Development, Roche
Ashley Lakner, Head, Oncology Discovery - pRED Oncology, Roche
Track 2: Breakthroughs in Translational Science, Imaging and Biomarkers 2
4:00PM - 4:20PM
Active Immunotherapy to Achieve Durable Remissions in MRD + AML
Speaker:
Erik Manting, PhD, CEO, Mendus
4:35PM - 4:55PM
Designing Next-Generation T-Cell Engagers for High Potency and Minimal Cytokine Release
Speaker:
Raffi Tonikian, PhD, Director, Translational Biomarkers, AbCellera
5:10PM - 5:25PM
Targeting Metastatic Cancer and Immune Resistance Using Nucleic Acid Therapies
Speaker:
Zdravka Medarova, PhD, CSO & Co-founder, TransCode Therapeutics
Track 3: Cell Therapy - Innovations in Process to Generate Cell Therapies
4:00PM - 4:15PM
Accelerating Cell Therapy: Innovations in Streamlining the Cell Manufacturing Process
Speaker:
Saba Ghassemi, PhD, Research Assistant; Professor of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
4:15PM - 4:30PM
Innovations in Point of Care and Extracorporeal Cell Delivery Technologies
Speaker:
Maurits Geerlings, MD, MBA, President & CEO, NanoCell Therapeutics, Inc
4:30PM - 4:45PM
In Vivo CD19 and CD22 CAR-T Cell Therapeutics for B Cell Malignancies
Speaker:
Andrew Scharenberg, MD, Co-Founder & CEO, Umoja Biopharma
4:45PM - 5:00PM
Implantable Biofactories for Bedside CAR T Cell Therapy
Speaker:
Yevgeny Brudno, PhD, Associate Professor, University of North Carolina at Chapel Hill and North Carolina State University
5:00PM - 5:15PM
Multiplexed CRISPR Cas9 Editing to Generate Next-Generation Allogeneic CAR-T Cells
Speaker:
Birgit Schultes, PhD, SVP, Head of Cell Therapies, Intellia Therapeutics
Track 4: Cell Therapy - Innovations in Cell Types Employed in Cell Therapies
4:00PM - 4:15PM
Advancing Cell Therapy Efficacy with Non-Viral Engineering Technologies
Speaker:
Loïc Vincent, PhD, CSO, Affini-T
4:15PM - 4:30PM
Peripheral Tumor Reactive Cells
Speaker:
Ruben Rodriguez, PhD, Head of Research, cTRL Therapeutics
4:30PM - 4:45PM
Engineered B Cells
Speaker:
Joanne Smith-Farrell, PhD, CEO & Director, Be Bio
4:45PM - 5:00PM
Clinical Biomarkers and Progress for Advancing Gamma-Delta CAR T Cells in Multiple Disease Settings
Speaker:
Blake Aftab, PhD, CSO, Adicet Bio
5:00PM - 5:15PM
Alternative Delivery Systems Spotlight Talks
Showing Events in 1 Track from 05:30pm to 06:30pm
IO360º Cancer Immunotherapy Debate
5:30PM - 6:30PM
IO360º Annual Debate: Monotherapy vs Combination Therapies in IO
Participants:
Alexander Eggermont, MD, PhD, CSO / Professor, Clinical & Translational Immunotherapy, Princess Máxima Center for Pediatric Oncology / UMC Utrecht, Utrecht University
Naiyer Rizvi, MD, CMO, Synthekine
Led by:
Daniel S Chen, MD, PhD, Founder, Engenuity Life Sciences

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.